An exploration section allowing simulation of a typical individual and an interactive exploration of parameters and treatments A simulation section allowing simulations of populations and clinical ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Lixoft division, a leading ...

Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled modelling in drug development. The partnerships aim to apply AI within ...

PARIS--(BUSINESS WIRE)--Lixoft, a Simulations Plus company (Nasdaq: SLP), a leading provider of population PKPD modeling solutions for pharmacometricians and biostatisticians, today announced that it ...

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that ...